ODYSSEY: Alirocumab Cuts CV Events, All-Cause Death Post-ACS

Share this post

First evidence of survival benefit with PCSK9 inhibitor alirocumab reignites the call for greater access to these expensive drugs for patients not just with ACS but also with stable atherosclerotic CVD.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply